<DOC>
	<DOCNO>NCT01056731</DOCNO>
	<brief_summary>This open-label , control , sequential , dose escalation study 16 week ' duration . The study compose two period : 0-2 week optional wash-out period depend previous antihypertensive treatment ( ) , follow 16-week open-label active treatment period . Patients evaluate every 4 week period 2 . Treatment start Aliskiren 150 mg dose titration Aliskiren 300 mg , addition HCTZ 12,5 mg 25 control BP achieve ( &lt; 140/90 mmHg 130/ 80 mmHg diabetic patient ) . All patient reach BP target consider meet primary endpoint visit consider final visit .</brief_summary>
	<brief_title>A Clinical Study With Aliskiren Alone Combination Therapy With Diuretic Hctz Venezuelan Hypertensive Patients .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Outpatients , essential hypertension , stage III , naïve control monotherapy . BP &gt; 180/110 mmHg Pregnant nursing woman Hypertensive encephalopathy cerebrovascular accident , transient ischemic cerebral attack , myocardial infarction , unstable angina , coronary bypass surgery , percutaneous coronary intervention within 6 month K &lt; 3.5 mEq/L ≥ 5 mEq/L Renal impairment Hypersensitivity HCTZ Aliskiren angioedema due ACEI ARB Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>high blood pressure</keyword>
	<keyword>aliskiren</keyword>
	<keyword>hydrochlorothiazide</keyword>
	<keyword>control rate</keyword>
</DOC>